Evidence map›Paper›PMID 32326377›Full record

ArticleCancers2020

STAT5 is Expressed in CD34

Emir Hadzijusufovic, Alexandra Keller, Daniela Berger, Georg Greiner, Bettina Wingelhofer, Nadine Witzeneder, Daniel Ivanov, Emmanuel Pecnard, Harini Nivarthi, Florian K M Schur and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. JAK-STAT Signaling in Autoimmunity and Cancer.ImmunoTargets and therapy · 2025
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 3 countries.

Emir HadzijusufovicLudwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0001-7409-4204
Alexandra KellerDepartment of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.
Daniela BergerLudwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria.
Georg GreinerDepartment of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria.
Bettina WingelhoferInstitute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, 1210 Vienna, Austria.ORCID 0000-0001-6108-5245
Nadine WitzenederDepartment of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria.
Daniel IvanovLudwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria.
Emmanuel PecnardINSERM, ERI-12, Faculté de Pharmacie, Université de Picardie Jules Verne, 80000 Amiens, France.
Harini NivarthiResearch Center for Molecular Medicine (CeMM), 1090 Vienna, Austria.
Florian K M SchurDepartment of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.
Yüksel FilikLudwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria.
Christoph KornauthDepartment of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.
Heidi A NeubauerInstitute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, 1210 Vienna, Austria.ORCID 0000-0001-7372-7786
Leonhard MüllauerDepartment of Pathology, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0002-3399-078X
Gary TinDepartment of Chemistry, University of Toronto, Toronto, ON M5S 1A1, Canada.
Jisung ParkDepartment of Chemistry, University of Toronto, Toronto, ON M5S 1A1, Canada.
Elvin D de AraujoDepartment of Chemistry, University of Toronto, Toronto, ON M5S 1A1, Canada.
Patrick T GunningDepartment of Chemistry, University of Toronto, Toronto, ON M5S 1A1, Canada.
Gregor HoermannDepartment of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria.
Fabrice GouilleuxINSERM, ERI-12, Faculté de Pharmacie, Université de Picardie Jules Verne, 80000 Amiens, France.ORCID 0000-0001-6047-1718
Robert KralovicsResearch Center for Molecular Medicine (CeMM), 1090 Vienna, Austria.
Richard MorigglInstitute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, 1210 Vienna, Austria.
Peter ValentLudwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0003-0456-5095
Medical University of Vienna · ATUniversity of Veterinary Medicine Vienna · ATUniversity of Toronto · CACeMM Research Center for Molecular Medicine · ATInserm · FRUniversité de Tours · FR

Funding

Austrian Science Fund FWF DOC 59Austrian Science Fund FWF I 4157
6 · The paper itself

Abstract

Janus kinase 2 (JAK2) and signal transducer and activator of transcription-5 (STAT5) play a key role in the pathogenesis of myeloproliferative neoplasms (MPN). In most patients,

Indexed as

JAK2 V617FMPNneoplastic stem cellsSTAT5

Identifiers

PMID32326377
PMCPMC7225958
OpenAlexW3019193608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.